Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ludotadipep
- Development stage
- Phase 2
- Lead developer
- FutureChem
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
Ludotadipep (also known as [177Lu]Ludotadipep or FC705) is a novel radiopharmaceutical developed by FutureChem for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It consists of a prostate-specific membrane antigen (PSMA)-targeting ligand labeled with the beta-emitting radioisotope lutetium-177. A distinguishing feature of Ludotadipep is the incorporation of a 4-iodophenyl butanoic group, which acts as an albumin-binding motif. This modification extends the drug's circulation time in the blood, thereby enhancing its uptake and retention within prostate tumor cells compared to first-generation PSMA-targeted radioligands. By binding to PSMA on the surface of cancer cells, the agent delivers targeted radiation, leading to DNA damage and cell death. It is currently being evaluated in Phase 2 clinical trials for safety and efficacy in patients with mCRPC.
- Other names
- [177Lu]Ludotadipep177Lu-LudotadipepLutetium (177Lu) Ludotadipep
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on Ludotadipep.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ludotadipep.